Set-up and largely funded by GlaxoSmithKline and Avalon Ventures, pharmaceuticals company Sitari has raised $10m in a series A round.

Editas Medicine, a genome editing company aiming to translate technology for turning disease-causing genes on or off into human therapeutics, raises $43m series A financing with participation of Partners Innovation Fund.

GSK and Avalon announce the first startup fruit of $495m biotech alliance announced in April.

Personalised immunotherapy developer Argos Therapeutics, backed by Genechem, extends series E financing from $42.5m to $60m.

Oxford University strikes licensing deal with Summit to develop drugs to combat Duchenne Muscular Dystrophy.

Biotech company Catabasis Pharmaceuticals raises $32.4m B funding led by Lightstone Ventures and including AstraZeneca's MedImmune Ventures, to pursue development of medicines to treat inflammatory and metabolic diseases.

Austrian vaccine developer Hookipa Biotech raises $27.5m series B funding supported by Boehringer Ingelheim Venture Fund and Takeda Ventures, to develop its lead vaccine for immunization against cytomegalovirus and to industrialize its Vaxwave technology for tackling infectious diseases and cancer.